Read by QxMD icon Read


Daniel Lavall, Andreas Hagendorff, Stephan H Schirmer, Michael Böhm, Michael A Borger, Ulrich Laufs
Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi-parametric approach. Severe secondary MR occurs in up to one-fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years. Percutaneous edge-to-edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics...
April 19, 2018: ESC Heart Failure
Gian Paolo Ussia, Valeria Cammalleri, Jawahar L Mehta, Kunal Sarkar, Saverio Muscoli, Pasquale de Vico, Giovanni Ruvolo, Francesco Romeo
AIMS: We report our experience with the CardiAQ prosthetic valve using both transapical and transseptal access. Aim of our study was proving the feasibility, safety and effectiveness of a novel transcatheter mitral valve bioprosthesis. METHODS: Four patients with severe mitral regurgitation, not eligible for mitral valve surgery, were treated with the CardiAQ valve. The procedures were performed under general anaesthesia, fluoroscopic and transesophageal echocardiographic guidance...
June 2017: Journal of Cardiovascular Medicine
Marco Barbanti, Corrado Tamburino
No abstract text is available yet for this article.
September 18, 2016: EuroIntervention
Francesco Romeo, Valeria Cammalleri, Giovanni Ruvolo, Arshad Quadri, Pasquale De Vico, Saverio Muscoli, Massimo Marchei, Sabrina Meloni, Fabio Conti, Gian Paolo Ussia
Trans-catheter mitral valve implantation (TMVI) is actually the most attractive technique for treating patients with severe mitral regurgitation, who are denied surgical therapy. Recently, trans-catheter implantation of aortic biological prosthesis in mitral position has been done in compassionate cases, and very few experiences of TMVI in native non-calcified valves have been recently reported in very-high-risk patients, mainly with functional mitral regurgitation.Here, we report our case of TMVI using the second-generation CardiAQ prostheisis (CardiAQ Valve Technologies, Irvine, California, USA), reviewing the current state of the art...
February 2016: Journal of Cardiovascular Medicine
Lars Sondergaard, Gian Paolo Ussia, Nicolas Dumonteil, Arshad Quadri
No abstract text is available yet for this article.
September 2015: EuroIntervention
Gian Paolo Ussia, Arshad Quadri, Valeria Cammalleri, Pasquale De Vico, Saverio Muscoli, Massimo Marchei, Giovanni Ruvolo, Lars Sondergaard, Francesco Romeo
AIMS: Transcatheter mitral valve implantation for mitral valve regurgitation is in the very early phase of development because of challenging anatomy and device dimensions. We describe the procedure of a transfemoral-transseptal implantation of the second-generation CardiAQ mitral valve bioprosthesis and 30-day follow-up. METHODS AND RESULTS: The procedure was performed percutaneously, without any left extracorporeal circulatory support. The patient had severe mitral regurgitation with severely depressed ventricular function and other comorbidities...
February 2016: EuroIntervention
Lars Søndergaard, Ole De Backer, Olaf W Franzen, Susanne J Holme, Nikolaj Ihlemann, Niels G Vejlstrup, Peter B Hansen, Arshad Quadri
No abstract text is available yet for this article.
July 2015: Circulation. Cardiovascular Interventions
Lars Sondergaard, Matthew Brooks, Nikolaj Ihlemann, Anders Jonsson, Susanne Holme, Mariann Tang, Kim Terp, Arshad Quadri
OBJECTIVES: As many as 50% of patients with severe symptomatic mitral valve regurgitation are denied surgical valve replacement or repair due to high operative risk. We describe an early series of cases of transcatheter implantation with a CardiAQ™ mitral valve via a transapical approach. METHODS: Three consecutive patients with an Society of Thoracic Surgeons (STS) mortality score of >22% were selected for transcatheter mitral valve implantation (TMVI) on compassionate grounds...
December 2015: European Journal of Cardio-thoracic Surgery
M Diamant, L Van Wolfswinkel, B Altorffer, D De Wied
The radiotelemetry system described in this paper consists of an implantable transmitter and a receiver, connected to a microcomputer. The hardware and software belonging to Mini-Mitters, for the collection and analysis of heart rate (HR), core temperature (CT), and gross activity data, do not possess the flexibility to detect acute changes in HR nor to discriminate among simultaneously occurring different types of behavior. In order to study short-term changes in HR in response to stress or drugs, in relation to behavioral responses, an inexpensive computer interface and a software program (CARDIAQ) were developed to collect data from Mini-Mitters...
June 1993: Physiology & Behavior
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"